Previous close | 964.47 |
Open | 970.00 |
Bid | 965.00 x 1000 |
Ask | 966.02 x 1000 |
Day's range | 959.49 - 970.71 |
52-week range | 684.81 - 998.33 |
Volume | |
Avg. volume | 530,555 |
Market cap | 105.363B |
Beta (5Y monthly) | 0.11 |
PE ratio (TTM) | 27.63 |
EPS (TTM) | 34.74 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1,036.19 |
A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness. The 2nd U.S. Circuit Court of Appeals in Manhattan said a lower court judge erred in dismissing the case, in part for having applied an improper legal standard to Regeneron's claims. Regeneron in a statement said it was "encouraged by the 2nd Circuit’s decision" and looked forward to "further advancing our position in future proceedings."
In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip our detailed analysis of the biotech sector, you can go directly to see the 5 Oversold Biotech Stocks To Buy Right Now. Dealmaking in Biotech Healthcare has been performing well so far in 2024, and […]
Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the...